PofoliaShared via Pofolia

Medical Mycology· 2017Q1

Closing the mycetoma knowledge gap

Wendy W. J. van de Sande, Ahmed Hassan Fahal, Sarah Ahmed, J. A. Serrano et al.

Short summary

Mycetoma, now a neglected tropical disease, has seen progress in understanding its prevalence, transmission, diagnosis, and treatment since 2013.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Over 9000 new mycetoma patients added to literature, updating prevalence maps.
  • Four novel mycetoma causative agents identified via molecular phylogeny, with one associated with Acacia trees.
  • Three isothermal amplification techniques and novel antigens developed for early diagnosis.
  • First randomized clinical trial for eumycetoma initiated, alongside in vitro susceptibility tests for black grain mycetoma.

AI-generated from the title and abstract; the full text is not read.

Abstract

On 28th May 2016, mycetoma was recognized as a neglected tropical disease by the World Health Organization. This was the result of a 4-year journey starting in February 2013 with a meeting of global mycetoma experts. Knowledge gaps were identified and included the incidence, prevalence, and mapping of mycetoma; the mode of transmission; the development of methods for early diagnosis; and better treatment. In this review, we review the road to recognition, the ISHAM working group meeting in Argentina, and we address the progress made in closing the knowledge gaps since 2013. Progress included adding another 9000 patients to the literature, which allowed us to update the prevalence map on mycetoma. Furthermore, based on molecular phylogeny, species names were corrected and four novel mycetoma causative agents were identified. By mapping mycetoma causative agents an association with Acacia trees was found. For early diagnosis, three different isothermal amplification techniques were developed, and novel antigens were discovered. To develop better treatment strategies for mycetoma patients, in vitro susceptibility tests for the coelomycete agents of black grain mycetoma were developed, and the first randomized clinical trial for eumycetoma started early 2017.

The authors' abstract, as published at the source. Medical Mycology, 2017 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Microbiology

MicrobiologyMedicine